Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
190 Leser
Artikel bewerten:
(1)

BIAL Foundation: Open nominations for the BIAL Award in Biomedicine 2025 with an increased amount to €350,000

Finanznachrichten News

Created to distinguish the most remarkable scientific discoveries in the biomedical field, this international award has been granted a growing reputation as a prelude to the Nobel Prize since it has distinguished in a former edition two authors subsequently honoured with the Nobel Prize in Medicine.

PORTO, Portugal, April 15, 2025 /PRNewswire/ -- The 4th edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is underway, with nominations open until 30 June. This edition, with a significant increase in the prize amount to 350,000 Euro, seeks to recognise work published in the broad biomedical field within the last 10 years, with results of exceptional quality and scientific relevance.

Prof. Ralph Adolphs, Bren Professor of Psychology, Neuroscience and Biology, and Director of the Emotion and Social Cognition Lab at the California Institute of Technology (Caltech), USA, and President of the Jury for the BIAL Award in Biomedicine

An independent Jury will choose the winning work among the high-quality empirical research papers in biomedicine published from 2016 onwards in peer-reviewed journals. The articles should be nominated by Scientific Societies, Heads of Medical Schools, Heads of Biomedical Research Institutes, Heads of prestigious Academies, Members of the Jury, Members of the Scientific Board of the BIAL Foundation, and previous winners of the BIAL Award. Self-nominations are not allowed.

Chaired by neuroscientist Ralph Adolphs, the Jury includes 12 more members designated by the European Research Council, Council of Rectors of Portuguese Universities, European Medical Association, Scientific Board of the BIAL Foundation, previous winners of the BIAL Award and editors of the British Medical Journal and the New England Journal of Medicine.

Ralph Adolphs challenges organised groups of scientists to nominate outstanding papers and stresses that "nominations are welcomed for articles authored by scientists at any stage of their career, and from any country around the world".

The chairman of the BIAL Foundation, Luís Portela, emphasises that "this Award aims to distinguish the work that has most contributed to improving the health conditions of humanity" and gives the example of "Drew Weissman and Katalin Karikó, co-authors of the winning paper of the 2021 edition, who were later awarded the Nobel Prize in Physiology or Medicine".

In the latest edition, this award honoured an article published in Nature in 2019 that represents pioneering research for understanding human cancer, specifically glioblastoma, a very aggressive type of brain tumour with an average survival time of just a year and a half. The winning team was led by Varun Venkataramani, Frank Winkler, and Thomas Kuner from Heidelberg University.

More information about this edition is available here.

BIAL Logo

Photo - https://mma.prnewswire.com/media/2646549/Ralph_Adolphs.jpg
Logo - https://mma.prnewswire.com/media/2585238/BIAL_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/open-nominations-for-the-bial-award-in-biomedicine-2025-with-an-increased-amount-to-350-000--302415795.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.